Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 105 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Katsiki, Niki  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
1
Anagnostis, P., Katsiki N., Adamidou F., Athyros V. G., Karagiannis A., Kita M., et al. (2013).  11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. Metabolism. 62(1), 21-33.
2
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. Curr Med Res Opin. 30(9), 1701-5.
A
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Achieving lipid targets in primary care settings.. Curr Med Res Opin. 30(10), 1971-4.
Katsiki, N., Yovos J. G., Gotzamani-Psarrakou A., & Karamitsos D. T. (2011).  Adipokines and vascular risk in type 2 diabetes mellitus.. Angiology. 62(8), 601-4.
Anagnostis, P., Katsiki N., Athyros V. G., & Karagiannis A. (2014).  Adiponectin and Aldosterone in Left Ventricular Hypertrophy: An Intriguing Interplay.. Angiology.
Katsiki, N., Mikhailidis D. P., Athyros V. G., & Karagiannis A. (2011).  Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance.. Circ J. 75(8), 2027; author reply 2028.
Mikhailidis, D. P., Katsiki N., Athyros V. G., & Karagiannis A. (2013).  Alcohol consumption and the heart.. Int J Cardiol. 168(4), 4319.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  Are statins 'IDEAL' for non-alcoholic fatty liver disease?. Curr Med Res Opin. 30(2), 229-31.
Katsiki, N., Mikhailidis D. P., Athyros V. G., Hatzitolios A. I., Karagiannis A., & Banach M. (2010).  Are we getting to lipid targets in real life?. Arch Med Sci. 6(5), 639-41.
Soulaidopoulos, S., Pagkopoulou E., Katsiki N., Triantafyllidou E., Karagiannis A., Garyfallos A., et al. (2019).  Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study.. Arthritis Res Ther. 21(1), 253.
B
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention.. Curr Med Res Opin. 30(1), 55.
C
Athyros, V. G., Tziomalos K., Katsiki N., Doumas M., Karagiannis A., & Mikhailidis D. P. (2015).  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World J Gastroenterol. 21(22), 6820-34.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.. Curr Med Res Opin. 29(7), 791-2.
Rizos, C. V., Elisaf M. S., Skoumas I., Tziomalos K., Kotsis V., Rallidis L., et al. (2018).  Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).. Atherosclerosis. 277, 308-313.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview.. Curr Vasc Pharmacol. 12(4), 627-41.
Athyros, V. G., Gossios T. D., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.. Arch Med Sci. 8(1), 6-10.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cold temperature and cardiovascular mortality.. Circ J. 77(11), 2846.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2015).  Contrast-Induced Nephropathy: An "All or None" Phenomenon?. Angiology. 66(6), 508-13.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
D
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2011).  The DEFINE study: a bright future for CETP inhibitors?. Expert Opin Investig Drugs. 20(3), 311-4.
Mantziari, L., Ziakas A., Ventoulis I., Kamperidis V., Lilis L., Katsiki N., et al. (2012).  Differences in Clinical Presentation and Findings between Idiopathic Dilated and Ischaemic Cardiomyopathy in an Unselected Population of Heart Failure Patients.. Open Cardiovasc Med J. 6, 98-105.
E
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές